MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury

Biochem Biophys Res Commun. 2003 Oct 24;310(3):936-42. doi: 10.1016/j.bbrc.2003.09.088.

Abstract

Monocyte chemoattractant protein (MCP)-1 is abundant in smooth muscle cells (SMC) and macrophages of atherosclerotic plaques and in the injured arterial wall. MCP-1 and its receptor, CCR2, are important mediators of macrophage accumulation and atherosclerotic plaque progression. We have recently reported that CCR2(-/-) mice have a approximately 60% decrease in intimal hyperplasia and medial DNA synthesis in response to femoral arterial injury. We have now examined the response to femoral arterial injury in MCP-1(-/-) mice. MCP-1 deficiency was associated with a approximately 30% reduction in intimal hyperplasia at 4 weeks and was not associated with diminished medial DNA synthesis. Despite inducing tissue factor in SMC culture, MCP-1 deficiency was not associated with a decrease in neointimal tissue factor after injury. These data suggest that MCP-1 and CCR2 deficiencies have distinct effects on arterial injury. The effects of MCP-1 on intimal hyperplasia may be mediated largely through SMC migration.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arteries / injuries*
  • Bromodeoxyuridine / pharmacology
  • Cell Division
  • Cell Movement
  • Chemokine CCL2 / deficiency*
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / physiology*
  • Chemokines / metabolism
  • DNA / biosynthesis
  • DNA / metabolism
  • Femoral Artery / pathology
  • Hyperplasia
  • Immunohistochemistry
  • Macrophages / metabolism
  • Mice
  • Mice, Transgenic
  • Muscle, Smooth / pathology
  • Receptors, CCR2
  • Receptors, Chemokine / metabolism
  • Tunica Intima / pathology*

Substances

  • Ccr2 protein, mouse
  • Chemokine CCL2
  • Chemokines
  • Receptors, CCR2
  • Receptors, Chemokine
  • DNA
  • Bromodeoxyuridine